Do Glucagon Like Peptide-۱ Receptor Agonists Modify Progression of Primary Glenohumeral Osteoarthritis? A Propensity Score–Matched Evaluation of Shoulder Arthroplasty Incidence

سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 25

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_TABO-14-11_004

تاریخ نمایه سازی: 22 آبان 1405

چکیده مقاله:

Objectives: Glenohumeral osteoarthritis (OA) is a common degenerative condition, and total shoulder arthroplasty (TSA) often represents the definitive treatment for end-stage disease. The use of glucagon-like peptide-۱ receptor agonists (GLP-۱RA) has increased substantially, and recent evidence suggests potential disease-modifying effects and reduced arthroplasty rates in lower-extremity joints. This study evaluated whether GLP-۱RA use is associated with progression from primary shoulder OA to TSA. Methods: A retrospective database query was performed to identify patients diagnosed with primary shoulder OA, excluding those with other shoulder pathologies. Patients were stratified according to prediagnosis GLP-۱RA prescription status and were ۱:۱ propensity-score matched to balance relevant comorbidities. Outcomes included the incidence of TSA, TSA-free survival assessed using Kaplan–Meier survival analysis, major joint injections, and mean levels of inflammatory biomarkers, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and cortisol. A significance threshold of P < ۰.۰۵ was applied. Results: After matching, each cohort included ۲۴,۶۶۹ patients. The GLP-۱RA cohort had a significantly shorter follow-up duration than the non-GLP-۱RA cohort (۷۳۱ ± ۶۹۴ vs. ۱,۲۲۰ ± ۱,۰۰۶ days; P < ۰.۰۰۱). TSA incidence was higher among GLP-۱RA users than among non-users (۲.۲۵% vs. ۱.۷۷%; P < ۰.۰۰۱), and TSA-free survival was lower in the GLP-۱RA cohort (۹۵.۵۰% vs. ۹۷.۲۳%; log-rank P < ۰.۰۰۱). A greater proportion of patients in the GLP-۱RA cohort received major joint injections (۱۸.۹۳% vs. ۱۶.۸۷%; P < ۰.۰۰۱), although the mean number of injections per patient was lower in this group (۲.۴۸ ± ۲.۸۶ vs. ۲.۷۴ ± ۳.۲۳; P < ۰.۰۰۱). GLP-۱RA users also demonstrated significantly lower mean CRP and ESR levels (both P < ۰.۰۰۱), while mean cortisol levels were similar between cohorts. Conclusion: In contrast to findings reported for hip and knee OA, GLP-۱RA use was not associated with a protective effect against progression to TSA in patients with primary shoulder OA. Further studies are warranted to clarify the joint-specific mechanisms that may underlie these differences. Level of evidence: III

نویسندگان

- -

Department of Orthopedic Surgery, Cleveland Clinic Foundation, Weston, Florida, USA

- -

Division of Shoulder and Elbow Surgery, Rothman Orthopaedic Institute, Philadelphia, PA, USA

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Ibounig T, Simons T, Launonen A, Paavola M. Glenohumeral osteoarthritis: ...
  • Chillemi C, Franceschini V. Shoulder osteoarthritis. Arthritis. ۲۰۱۳;۲۰۱۳:۳۷۰۲۳۱. doi:۱۰.۱۱۵۵/۲۰۱۳/۳۷۰۲۳۱ ...
  • Wagner ER, Farley KX, Higgins I, Wilson JM, Daly CA, ...
  • Collins L, Costello RA. Glucagon-Like Peptide-۱ Receptor Agonists. StatPearls. ۲۰۲۵ ...
  • Watanabe JH, Kwon J, Nan B, Reikes A. Trends in ...
  • Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-۱: ...
  • Cheng J, Solomon T, Estee M, Cicuttini FM, Lim YZ. ...
  • Lavu MS, Porto JR, Hecht II CJ, et al. The ...
  • Porto JR, Lavu MS, Hecht CJ, et al. The Impact ...
  • Chen J, Xie JJ, Shi KS, et al. Glucagon-like peptide-۱ ...
  • Li H, Chen J, Li B, Fang X. The protective ...
  • Mei J, Sun J, Wu J, Zheng X. Liraglutide suppresses ...
  • Meurot C, Martin C, Sudre L, et al. Liraglutide, a ...
  • Tong C, Liang H, Liu X, et al. The protective ...
  • Zhang X, Jiang J, Xu J, Chen J, Gu Y, ...
  • Zhu H, Zhou L, Wang Q, et al. Glucagon-like peptide-۱ ...
  • Bliddal H, Bays H, Czernichow S, et al. Once-Weekly Semaglutide ...
  • Bartholdy C, Overgaard A, Gudbergsen H, Bliddal H, Kristensen LE, ...
  • Davis WR, Bank NC, Lauck BJ, Creighton RA, Mistovich RJ. ...
  • Dainese P, Mahieu H, De Mits S, Wittoek R, Stautemas ...
  • Jin X, Beguerie JR, Zhang W, et al. Circulating C ...
  • Pearle AD, Scanzello CR, George SS, et al. Elevated C-reactive ...
  • Smith JW, Martins TB, Gopez E, Johnson T, Hill HR, ...
  • Haj Shehadeh T, Chaudhry J, Abdeen A, Updegrove G, Armstrong ...
  • نمایش کامل مراجع